Phaseline

Targets › GDNF

GDNF (Glial cell line-derived neurotrophic factor): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 2; Neurology, Ophthalmology; next expected readout Jun 2027.

Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake. Acts by binding to its coreceptor, GFRA1, leading to autophosphorylation and activation of the RET receptor. (UniProt, P39905)

Open in Phaseline: the race on GDNF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AskBioAAV2-GDNF
Adeno-associated virus serotype 2 delivering glial cell line-derived neurotrophic factor (
GDNFPhase 2Parkinson DiseaseAug 2028
Brain Neurotherapy BioAAV2-GDNF
AAV2-delivered GDNF gene therapy
GDNFPhase 1Parkinson's Disease; Multiple System AtrophyJun 2027
Cedars-Sinai Medical CenterCNS10-NPC-GDNF
Neural progenitor cells engineered to produce glial cell line-derived neurotrophic factor
GDNFPhase 1Retinitis Pigmentosa; Amyotrophic Lateral Sclerosis–

Conditions

Parkinson's Disease (1) Multiple System Atrophy (1) Retinitis Pigmentosa (1) Amyotrophic Lateral Sclerosis (1) Parkinson Disease (1)

Modalities

other (2), protein or peptide (1)

Companies

Brain Neurotherapy Bio (1) Cedars-Sinai Medical Center (1) AskBio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.